Advertisement
PACB vs STIM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PACB is a Hold and STIM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PACB’s FA Score shows that 0 FA rating(s) are green whileSTIM’s FA Score has 1 green FA rating(s).
- PACB’s FA Score: 0 green, 5 red.
- STIM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PACB’s TA Score shows that 3 TA indicator(s) are bullish while STIM’s TA Score has 3 bullish TA indicator(s).
- PACB’s TA Score: 3 bullish, 7 bearish.
- STIM’s TA Score: 3 bullish, 7 bearish.
Price Growth
PACB (@Medical/Nursing Services) experienced а -9.66% price change this week, while STIM (@Medical/Nursing Services) price change was +3.10% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.24%. For the same industry, the average monthly price growth was +4.07%, and the average quarterly price growth was -14.05%.
Reported Earning Dates
PACB is expected to report earnings on Aug 05, 2026.
STIM is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.24% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| PACB | STIM | PACB / STIM | |
| Capitalization | 407M | 92.6M | 440% |
| EBITDA | -103.11M | -26.07M | 396% |
| Gain YTD | -29.947 | -3.623 | 827% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 160M | 152M | 105% |
| Total Cash | 276M | 13.5M | 2,044% |
| Total Debt | 703M | 85.4M | 823% |
PACB | STIM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 60 | 64 | |
P/E GROWTH RATING 1..100 | 73 | 100 | |
SEASONALITY SCORE 1..100 | 46 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STIM's Valuation (24) in the Medical Specialties industry is significantly better than the same rating for PACB (100) in the Biotechnology industry. This means that STIM’s stock grew significantly faster than PACB’s over the last 12 months.
STIM's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that STIM’s stock grew similarly to PACB’s over the last 12 months.
STIM's SMR Rating (99) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that STIM’s stock grew similarly to PACB’s over the last 12 months.
PACB's Price Growth Rating (60) in the Biotechnology industry is in the same range as STIM (64) in the Medical Specialties industry. This means that PACB’s stock grew similarly to STIM’s over the last 12 months.
PACB's P/E Growth Rating (73) in the Biotechnology industry is in the same range as STIM (100) in the Medical Specialties industry. This means that PACB’s stock grew similarly to STIM’s over the last 12 months.
| PACB | STIM | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 83% | 8 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 87% | 4 days ago 76% |
| Momentum ODDS (%) | 4 days ago 90% | 4 days ago 88% |
| MACD ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 90% | 4 days ago 82% |
| TrendMonth ODDS (%) | 4 days ago 81% | 4 days ago 84% |
| Advances ODDS (%) | 15 days ago 83% | 4 days ago 84% |
| Declines ODDS (%) | 4 days ago 90% | 8 days ago 90% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 86% | 5 days ago 89% |
Advertisement
STIM and
Correlation & Price change
A.I.dvisor tells us that STIM and CBLL have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that STIM and CBLL's prices will move in lockstep.
| Ticker / NAME | Correlation To STIM | 1D Price Change % | ||
|---|---|---|---|---|
| STIM | 100% | +1.53% | ||
| CBLL - STIM | 32% Poorly correlated | +1.76% | ||
| PACB - STIM | 28% Poorly correlated | -2.96% | ||
| ALGN - STIM | 27% Poorly correlated | -0.95% | ||
| BMRA - STIM | 26% Poorly correlated | -1.91% | ||
| NEO - STIM | 26% Poorly correlated | -2.79% | ||
More | ||||